跳至主要内容
临床试验/NCT05512559
NCT05512559Enrolling By Invitation不适用

Value of Body Composition Analysis in Predicting Delayed Emergence From Remimazolam-based General Anesthesia: A Prospective Observational Study.

Samsung Medical Center1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2022年9月5日最近更新:
适应症

试验速览

阶段
不适用
状态
Enrolling By Invitation
入组人数
90
试验地点
1
主要终点
emergence time

研究概览

简要总结

Remimazolam is a novel general anesthetic drug. The time to emergence from remimazolam-based general anesthesia is variable among patients, but little is known about the risk factors for delayed emergence. We believe that information from body composition analysis may be helpful in understanding which patients are more likely to show delayed emergence from remimazolam.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult ASA I-III patients undergoing cerebral aneurysm coil embolization under general anesthesia using remimazolam

排除标准

  • Patients with preoperative mental change, hemodynamic instability, hemodialysis, heart failure, hypoalbuminemia, pregnancy

结局指标

主要结局

emergence time

时间窗: at the time of emergence

relationship between body composition analysis information and time to emergence after discontinuing remimazolam infusion.

次要结局

  • time to loss of consciousness(at the time of induction)
  • hypotension(from induction to emergence of anesthesia)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jong Hwan Lee

Professor

Samsung Medical Center

研究点 (1)

Loading locations...

相似试验

Body Composition Analysis and Time to Emergence From... | 临床试验